4D Molecular Therapeutics (FDMT) Capital Expenditures (QoQ) (2020 - 2026)
4D Molecular Therapeutics (FDMT) Capital Expenditures (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -102.69% |
| Mar 31, 2026 | 448.96% |
| Dec 31, 2025 | 4,848.35% |
| Sep 30, 2025 | -116.34% |
| Jun 30, 2025 | 297.86% |
| Mar 31, 2025 | -85.25% |
| Dec 31, 2024 | -46.63% |
| Sep 30, 2024 | 409.46% |
| Jun 30, 2024 | -50.85% |
| Mar 31, 2024 | 135.71% |
| Dec 31, 2023 | -204.08% |
| Sep 30, 2023 | 372.86% |
| Jun 30, 2023 | -169.17% |
| Mar 31, 2023 | 330.00% |
| Dec 31, 2022 | 94.52% |
| Sep 30, 2022 | -488.58% |
| Jun 30, 2022 | -67.78% |
| Mar 31, 2022 | 25.84% |
| Dec 31, 2021 | 38.97% |
| Sep 30, 2021 | 1,715.35% |